Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 131, Issue 19

May 10 2018

In this Issue

BLOOD COMMENTARIES
PLENARY PAPER
PERSPECTIVE
CLINICAL TRIALS AND OBSERVATIONS
LYMPHOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
LETTER TO BLOOD
BLOOD WORK

Table of Contents

BLOOD COMMENTARIES

THROMBOSIS AND HEMOSTASIS

The antiphospholipid syndrome finally fathomed?

Philip G. de Groot

View Articletitled, The antiphospholipid syndrome finally fathomed?

THROMBOSIS AND HEMOSTASIS

“Antiphospholipids”: the more, the worse?

Denis Wahl

View Articletitled, “Antiphospholipids”: the more, the worse?

THROMBOSIS AND HEMOSTASIS

Tissue factor and oxidative stress

Nigel Mackman,Silvio Antoniak

View Articletitled, Tissue factor and oxidative stress

PLENARY PAPER

THROMBOSIS AND HEMOSTASIS

Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium

Anastasia Sacharidou,Ken L. Chambliss,Victoria Ulrich,Jane E. Salmon,Yu-Min Shen,Joachim Herz,David Y. Hui,Lance S. Terada,Philip W. Shaul,Chieko Mineo

View Articletitled, Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium

Supplemental data

PERSPECTIVE

The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis

Rafael Kramann,Rebekka K. Schneider

View Articletitled, The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis

CLINICAL TRIALS AND OBSERVATIONS

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Clinical Trials & Observations Brief Report

Michelle A. Fanale,Steven M. Horwitz,Andres Forero-Torres,Nancy L. Bartlett,Ranjana H. Advani,Barbara Pro,Robert W. Chen,Andrew Davies,Tim Illidge,Mayur Uttarwar,Shih-Yuan Lee,Hong Ren,Dana A. Kennedy,Andrei R. Shustov

View Articletitled, Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Supplemental data

LYMPHOID NEOPLASIA

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas

Malik Bisserier,Narendra Wajapeyee

View Articletitled, Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas

Supplemental data

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

Yi Jin,Kenian Chen,Ayla De Paepe,Eva Hellqvist,Aleksandra D. Krstic,Lauren Metang,Charlotte Gustafsson,Richard E. Davis,Yair M. Levy,Rakesh Surapaneni,Ann Wallblom,Hareth Nahi,Robert Mansson,Yin C. Lin

View Articletitled, Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

Supplemental data

THROMBOSIS AND HEMOSTASIS

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism
Clinical Trials & Observations

Clive Kearon,Sameer Parpia,Frederick A. Spencer,Trevor Baglin,Scott M. Stevens,Kenneth A. Bauer,Steven R. Lentz,Craig M. Kessler,James D. Douketis,Stephan Moll,Scott Kaatz,Sam Schulman,Jean M. Connors,Jeffrey S. Ginsberg,Luciana Spadafora,Vinai Bhagirath,Patricia C. Liaw,Jeffrey I. Weitz,Jim A. Julian

View Articletitled, Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism

Supplemental data

Paraoxonase-2 regulates coagulation activation through endothelial tissue factor

Julia Ebert,Petra Wilgenbus,John F. Teiber,Kerstin Jurk,Kathrin Schwierczek,Mareike Döhrmann,Ning Xia,Huige Li,Lisa Spiecker,Wolfram Ruf,Sven Horke

View Articletitled, Paraoxonase-2 regulates coagulation activation through endothelial tissue factor

Supplemental data

LETTER TO BLOOD

Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome

Chikako Ohwada,Emiko Sakaida,Chika Kawajiri-Manako,Yuhei Nagao,Nagisa Oshima-Hasegawa,Emi Togasaki,Tomoya Muto,Shokichi Tsukamoto,Shio Mitsukawa,Yusuke Takeda,Naoya Mimura,Masahiro Takeuchi,Naomi Shimizu,Sonoko Misawa,Tohru Iseki,Satoshi Kuwabara,Chiaki Nakaseko

View Articletitled, Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome

Supplemental data

BLOOD WORK

Pautrier-like microabscesses in the tonsil

Ikuo Matsuda,Seiichi Hirota

View Articletitled, Pautrier-like microabscesses in the tonsil

Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia

Oluwaseun O. Olaiya,Weijie Li

View Articletitled, Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia

Cover Image

Cover Image

Paraoxonase-2 (PON2)–deficient aorta stained for superoxide (red) and collagen (green). Vascular oxidative stress by PON2 deficiency causes prothrombotic states through endothelial tissue factor (TF) activation. The authors identify a link from PON2-controlled oxidative stress to endothelial TF decryption and coagulation. See the article by Ebert et al on page 2161.
Front Matter
Table of Contents
Back Matter
Editorial Board

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma

High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Doubling down on GPRC5D in multiple myeloma

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Current Issue
First edition
All Issues

Collections
Abstracts
Authors

Submit to Blood
About Blood
Subscriptions

Public Access
Permissions
Alerts

Contact Us
Newsroom
Blood Classifieds

Advertising in Blood
Terms and Conditions
Twitter

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright 2024 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals